acetyl l carnitine gut motility Metabotherapy for intestinal disease: using metabolites to prevent and treat disorders of the Frontiers | Carnitine Traffic in

F.JohnG

[DOI] [PMC free article] [PubMed] [Google Scholar] 109.Moro C, Crampes F, Sengenes C, De Glisezinski I, Galitzky J, Thalamas C, et al

Glossary AE Adverse event APC Antigen-presenting cells BCPNN Bayesian confidence propagation neural network CD Cluster of differentiation CI Confidence interval CRS Cytokine release syndrome dICI Dual immune checkpoint inhibitor/Ipilimumab+Nivolumab or Tremelimumab+Durvalumab DIG Dual immunotherapy group/Ipilimumab+Nivolumab and Tremelimumab+Durvalumab FAERS The US Food and Drug Administration Adverse Event Reporting System IC 025 95% CI lower limit of information component ICI Immune checkpoint inhibitor irAE Immune-related adverse event MedDRA Medical Dictionary for Regulatory Activities NSCLC Non-small cell lung cancer PS Primary suspect PT Preferred term Q1 Lower quartile Q3 Upper quartile ROR Reporting odds ratio ROR 025 95% CI lower limit of ROR SD Standard deviation sICI Single immune checkpoint inhibitor SOC System organ class Treg Regulatory T cell

Upon binding to transferrin receptor (TfR1) at the cell surface, TF-Fe + enters the cell via endocytosis

"Autism and attention-deficit/hyperactivity disorders and symptoms in children with neurofibromatosis type 1"